Simmiparib | Interleukin Related interleukin-related.com

Product Name :
Simmiparib

Search keywords :
Simmiparib

drugId :
null

Target Vo:
Poly (ADP-Ribose) Polymerase 2

Target Vo Short Name :
PARP-2

Moa_Name:
Poly (ADP-Ribose) polymerase 1 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

Active Company_Name :
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

Active Indication_Name:
Breast Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:
Phase 1 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Oct-4 Rabbit pAb web
Andecaliximab Technical Information
PARP1 Antibody (YA245): PARP1 Antibody (YA245) is a non-conjugated and Rabbit origined monoclonal antibody about 113 kDa, targeting to PARP1. It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts